Disruptive Pharma AB
1.09
SEK
+0.07
(+6.67%)
ISIN
SE0021181559
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Peter Åsberg
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Uppsala Sweden
- IPO Date
- Apr 3, 2013
- Website
- disruptivepharma.com
- Similar Companies
- Business
- Disruptive Pharma AB is a Sweden-based pharmaceutical technology and drug delivery company engaged in the development and commercialization of advanced materials designed to enhance the solubility, dissolution rate, and oral bioavailability of poorly soluble active pharmaceutical ingredients (APIs). The company operates within the pharmaceutical formulation and drug delivery segment of the life sciences sector, targeting global biotechnology and pharmaceutical companies seeking lifecycle management solutions and formulation optimization for Biopharmaceutics Classification System (BCS) Class II and Class IV compounds. Disruptive Pharma's primary proprietary offerings and service capabilities comprise Formulite, a patented drug delivery platform based on engineered mesoporous magnesium carbonate (MMC) that stabilizes active drug compounds in an amorphous state through nanoporous confinement; formulation feasibility screening and pre-formulation assessment services to evaluate material compatibility, drug loading capacity, and dissolution kinetics; formulation development and optimization services for conventional solid oral dosage forms, including tablets, capsules, and powder formulations; analytical method development, solid-state physicochemical characterization, and stability testing; technology transfer, manufacturing scale-up, and process engineering support in collaboration with contract development and manufacturing organizations (CDMOs); and intellectual property out-licensing and co-development partnership models for new chemical entities (NCEs), repurposed therapeutics, and value-added formulations. The underlying technology originated from nanoscience research at Uppsala University and was established as a dedicated enterprise in 2021 as a spin-out from Disruptive Materials AB, while the listed parent corporate structure dates back to 2008. The company is headquartered in Uppsala, Sweden, with corporate offices in Stockholm, Sweden, and serves commercial partners and research collaborators internationally across Europe and North America. In recent developments, the company underwent a major corporate and strategic restructuring in July 2026 when Guard Therapeutics International AB completed a reverse takeover of Disruptive Pharma Holding AB, subsequently renaming the combined entity Disruptive Pharma AB (publ) and updating its ticker symbol on the Nasdaq First North Growth Market from GUARD to DPHA. Following the transaction, the company reoriented its operational focus entirely toward the commercial development, partner integration, and industrial scaling of the Formulite drug delivery platform. In September 2026, Disruptive Pharma entered into a definitive agreement to divest its non-core legacy GTX therapeutic asset platform to Aurelia Invest AB, retaining rights to future potential royalties and milestone payments. In addition, the company has actively broadened its strategic alliances and industrial collaborations with global CDMOs to enable commercial-scale manufacturing and accelerate partner pipeline adoption.